Phase II study of disitamab vedotin (RC48) in combination with tislelizumab and bevacizumab in patients (Pts) with HER2 alterations locally advanced or metastatic NSCLC: Primary analysis results of ...
Observational studies are critical in evaluating the long-term safety and effectiveness of new therapies on patients’ lives. However, two major shifts are significantly changing the research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results